Yoltech Therapeutics, one of China’s most prolific gene editing companies has raised its biggest round of funding ahead of plans to go public in Hong Kong.
One of China’s most prolific gene editing companies has raised its biggest round of funding yet, ahead of plans to go public in Hong Kong.
…
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SR One’s Simeon George on how China is rewriting biotech’s venture playbook
Allogene CEO David Chang stepping down
Prime Venture, Leo Capital back biotech startup StrainX in $13M round
Biotech startup StrainX Bioworks raises $13 million from Prime Venture, Leo Capital, others - The Economic Times
Five biotech news updates to stay on top of today
New York City-based startup Waypoint Bio has raised $20 million in series A financing to test multiple cell therapies in China.
Chinese companies dominate global gene therapy competition with 48 programs vs 20 in US, targeting expensive Western treatments…
Technique to precisely edit large DNA segments could transform disease research, crop breeding, experts say.
The stigmatized idea could get a massive boost from “tech bros”—and some scientists are cheering them on.
Over the past year, I’ve begun hearing rumblings from scientists who secretly think it’s time to stop being stodgy about editing…
The so-called NewCo model of value creation has been around for years, but its use with assets connected to China appears to be…
